Expect Eli Lilly & Co to start giving analysts and investors some color on its Alzheimer's disease program by the end of 2016. Lilly revealed during its first quarter earnings call 23 April that the last patient visit in its study of its recently resurrected AD drug solanezumab is now expected in late 2016 – topline data should follow months later.
"I'm also pleased to announce that we have completed enrollment of the EXPEDITION 3 trial evaluating solanezumab in amyloid positive...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
